Study finds increase in cannabis-related disorders among pregnant women post legalization

In October 2018, Canada enacted the Cannabis Act in Canada (CAC), which legalised the non-medical use of cannabis. A new study has found that the rate of cannabis-related disorders diagnosed among pregnant women in the Canadian province of Québec increased by more than 20% after the enactment of the CAC, while rates for all other drug- and alcohol-related disorders remained stable. The study is published today in the scientific journal Addiction.

This study measured changes to the monthly rates of diagnosed cannabis-related disorders (CRDs) in the pregnant population in Québec. Since 2010 the monthly average number of CRDs has increased consistently, and before October 2018, the average number of CRD diagnoses per month was 14.5 per 100,000 pregnant women. After October 2018, the average number of CRD diagnoses per month jumped to 23.5 per 100,000 pregnant women and has remained at that higher level. There were no significant changes for any other drug- and alcohol-related disorders in the same period. 

The study looked at rates of CRD diagnoses in pregnant women aged 15 to 49 years in the Canadian province of Québec between January 2010 and July 2021. Data were sourced from the Québec Integrated Chronic Disease Surveillance System (QICDSS). Given that approximately 98% of the Québec population is eligible and admissible to public health insurance, the QICDSS encompasses data for nearly the entire population of the province.

Cannabis use during pregnancy has been associated with elevated risk of preterm birth, neonatal intensive care unit admissions, low birth weight, and other negative outcomes, so the increase in CRD diagnoses after the Cannabis Act should trigger a robust public health response. Our study highlights the importance of universal screening for CRDs. Additionally, pregnant women with a history of cannabis disorder may benefit from repeated screening and ad-hoc counseling during pregnancy."

José Ignacio Nazif-Munoz, Lead Author, Professor of the Université de Sherbrooke

Source:
Journal reference:

Nazif-Munoz, J. I., et al. (2024) Changes in prenatal cannabis-related diagnosed disorders after the Cannabis Act and the COVID-19 pandemic in Quebec, Canada. Addictiondoi.org/10.1111/add.16564.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How may cannabis affect neurodevelopment when exposed in the womb?